Gilead shares slide after FDA knocks back rheumatoid arthritis drug – Reuters

Gilead shares slide after FDA knocks back rheumatoid arthritis drug – Reuters

Shares of Gilead Sciences fell 3% after the U.S. Food and Drug Administration declined to approve its experimental rheumatoid arthritis treatment, a major setback for one of the drugmaker’s important products.

Read More…

You May Also Like